Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.
Non-Small Cell Lung Cancer News
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Could a Blood Test Spot Lung Cancer Early?
Posted 4 Jun 2018 by Drugs.com
SATURDAY, June 2, 2018 – Genetic blood testing is showing potential as a means of catching some early stage cancers, researchers are reporting. For example, a panel of three different genetic tests was able to detect early stage lung cancer about half of the time in people who'd already been diagnosed with the disease. The tests also detected late-stage lung cancers about 9 out of 10 times, the ...
Cancer Drug Keytruda a New Weapon Against Advanced Lung Tumors
Posted 4 Jun 2018 by Drugs.com
SUNDAY, June 3, 2018 – A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows. Keytruda (pembrolizumab) extended life four to eight months longer than chemotherapy in lung cancer patients whose immune systems had been duped by their cancer cells. "This trial shows that pembrolizumab used alone improves survival as opposed to ...
Lung Cancer Rate Now Higher in Young Women Than Young Men
Posted 24 May 2018 by Drugs.com
WEDNESDAY, May 23, 2018 – In a reversal of historical patterns, lung cancer is now more common among young U.S. women than men, a new study finds. The good news, researchers found, is that over the past two decades, lung cancer rates among 35- to 54-year-old Americans have dropped across the board. But the decline has been steeper among men so that now, incidence of the disease is higher in ...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
Posted 23 Apr 2018 by Drugs.com
18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test. The approval is based on ...
New Immunotherapy Drugs May Be Big Advance in Lung Cancer Care
Posted 16 Apr 2018 by Drugs.com
MONDAY, April 16, 2018 – Drugs designed to trigger a patient's immune system may help boost survival for those battling lung cancer, two new studies found. The first study found that when the immunotherapy drug Keytruda (pembrolizumab) was combined with standard chemotherapy, the chance that a patient would die within the next 11 months plummeted by more than 50 percent, compared with being ...
More Women Die of Lung Cancer in 2 U.S. 'Hot Spots'
Posted 31 Mar 2018 by Drugs.com
FRIDAY, March 30, 2018 – Lung cancer death rates among women have fallen in much of the United States, but have increased in two regions where smoking is more common, a new study finds. The first cluster or "hot spot" comprises 669 counties in Appalachia and the Midwest, and the second is 81 counties in the northern Midwest, according to the analysis of U.S. National Cancer Institute data. ...
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
Posted 14 Mar 2018 by Drugs.com
PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.1 This approval will provide health care ...
Presidential Panel Says High-Priced Cancer Drugs Harm Patient Care
Posted 13 Mar 2018 by Drugs.com
TUESDAY, March 13, 2018 – "Financial toxicity" caused by high cancer drug prices is harming people's ability to fight the dreaded disease, a new report from the President's Cancer Panel warns. The report, released Tuesday, argues that urgent action is needed to stem the growing price tags associated with new cancer drugs, particularly if the price doesn't match the amount of benefit the drug ...
Young Cancer Survivors Finding Support From Social Networks
Posted 9 Mar 2018 by Drugs.com
FRIDAY, March 9, 2018 – Social networks and support appear to be stronger among teen and young adult cancer survivors than among their peers who haven't had cancer, a new study has found. Overall, the cancer survivors were found to have more emotional and other types of support and to get more advice on health topics such as physical activity and weight. The 204 participants in the study ...
Health Tip: Understanding Palliative Care
Posted 21 Feb 2018 by Drugs.com
-- Palliative care is designed to improve the quality of life and help manage the symptoms of a serious iilness, the U.S. National Institutes of Health says. The focus is on keeping a person comfortable and happy, and can be provided alongside treatment. Palliative care can be provided in nursing homes, outpatient clinics, residences and hospitals, and often is covered by private insurance, ...
Tobacco Kills, No Matter How It's Smoked: Study
Posted 20 Feb 2018 by Drugs.com
TUESDAY, Feb. 20, 2018 – Smokers who think cigars or pipes are somehow safer than cigarettes may want to think again, new research indicates. The study tracked the health and habits of more than 357,000 Americans from 1985 to 2011. It found that, compared to people who had never smoked, people who regularly smoked only cigarettes had double the risk of death in that time frame, from whatever the ...
FDA Approves Imfinzi (durvalumab) for Unresectable Stage III Non-Small Cell Lung Cancer
Posted 18 Feb 2018 by Drugs.com
February 16, 2018 – The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III u ...
Lung Cancer One of Many Reasons Not to Smoke
Posted 18 Feb 2018 by Drugs.com
SUNDAY, Feb. 18, 2018 – You already know that smoking causes lung cancer. But tobacco use can lead to other major health problems, too, experts warn. "Cigarette smoking is probably the single most harmful thing you can do to your health," said Jonathan Foulds, a professor of public health sciences and psychiatry at Penn State College of Medicine. "It's hard to find a part of the body not ...
Exercise May Help Lung Cancer Surgery Go More Smoothly
Posted 2 Feb 2018 by Drugs.com
FRIDAY, Feb. 2, 2018 – Lung cancer patients can halve their risk of postop complications by taking up an exercise program before their surgery, a new report suggests. For the study, researchers analyzed reports on 13 clinical trials that included a total of over 800 people who had surgery for cancer. The patients had been treated for cancer of the bowel, liver, esophagus, lung, mouth or ...
Health Tip: Select the Right Cancer Team
Posted 31 Jan 2018 by Drugs.com
-- If you've been diagnosed with cancer, choosing the medical team that will treat you is a hugely important decision. The American Cancer Society offers these suggestions: Ask the doctor who diagnoses you where he or she would recommend going for treatment. Consult with family and friends who have had cancer to see what they'd suggest. Identify a cancer center that has a history of treating ...
Further Information
Related Condition Support Groups
Related Drug Support Groups
methotrexate, Tarceva, Avastin, Opdivo, Keytruda, Taxol, Xalkori, Taxotere, cisplatin, view more... capecitabine, nivolumab, cyclophosphamide, Gemzar, paclitaxel, Tecentriq, gemcitabine, erlotinib, Iressa, pembrolizumab, Cyramza, crizotinib, Abraxane, Mekinist, Tagrisso, Platinol, Navelbine, Gilotrif, Alimta, bevacizumab, vinorelbine, docetaxel, afatinib, ramucirumab, gefitinib, cetuximab, osimertinib, Tafinlar, Methotrexate LPF Sodium, Imfinzi, pemetrexed, Mvasi, Alecensa, Portrazza, Alunbrig, paclitaxel protein-bound, Zykadia, porfimer, durvalumab, dabrafenib, brigatinib, trametinib, Platinol-AQ, Folex PFS, ceritinib, Photofrin, necitumumab, Onxol, Trexall, alectinib, atezolizumab, Docefrez
